A study of 77 patients treated in seven centers in Hungary indicated that treatment with the oral triple combination regimen of Ninlaro, or ixazomib, Revlimid, or lenalidomide, and dexamethasone extended time to disease progression or death in patients with multiple myeloma who had received prior treatment. The data were reported in the journal Pathology & Oncology Research.
Oral triple combo benefits patients with advanced multiple myeloma
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.